Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

por Tural, D, Serdengecti, S, Demirelli, F, Öztürk, T, İlvan, S, Turna, H, Özgüroglu, M, Büyükünal, E
Publicado 2014

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

por Tural, D, Serdengecti, S, Demirelli, F, Öztürk, T, İlvan, S, Turna, H, Özgüroglu, M, Büyükünal, E
Publicado 2014

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

por Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., Sartor, A. O.
Publicado 2013

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

por Senan, S., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Murakami, S., Hui, R., Faivre-Finn, C., Paz-Ares, L., Wu, Y.L., Mann, H., Dennis, P.A., Antonia, S.J.
Publicado 2022

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

por Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M.J., Özgüroğlu, M., Ji, J.H., Garassino, M.C., Voitko, O., Poltoratskiy, A., Musso, E., Havel, L., Bondarenko, I., Losonczy, G., Conev, N., Mann, H., Dalvi, T.B., Jiang, H., Goldman, J.W.
Publicado 2022